Investment
Features
FeesSafety
Academy
More
Pluang+

Sunstone Hotel Investors to report Q3 2026 earnings on Nov 6 before market opens

Company Fundamentals
18 Sep 2026
PRNewsWire
View Source
Neutral
Sunstone Hotel Investors to report Q3 2026 earnings on Nov 6 before market opens

Sunstone Hotel Investors, a lodging real estate investment trust, announced it will release its financial results for the third quarter of 2026 on November 6, before the market opens. The company will hold a conference call at 12:00 p.m. Eastern Time on the same day to discuss the results, accessible via webcast or phone. This update is important for investors tracking the hotel and resort real estate sector and Sunstone's performance. A transcript of the call will be available on Sunstone's website for further review.

Sunstone Hotel Investors' upcoming third quarter 2026 earnings release is noted alongside Pluang's real estate sector data. For readers following real estate stocks, here is Pluang's market snapshot as of Sep 18, 2026 17:42 WIB: Among 24 priced US real estate stocks, 16 rose and 6 fell. Alexandria Real Estate Equities Inc (ARE) traded at USD 56.00 with a 1-day change of -0.60% and a typical hold time of 92 days, while Prologis Inc (PLD) was at USD 134.51, down 0.50%, with a 101-day hold time and 91% sell order activity. Apartment Investment and Management Co (AIV) rose 0.45% to USD 2.23, with a typical hold time of 71 days and 79% buy order activity.

More News

Duke Energy's stock shows 8.26% upside with strong earnings forecast and mixed institutional interest.

Duke Energy's stock shows 8.26% upside with strong earnings forecast and mixed institutional interest.

Duke Energy Corporation's stock is projected to rise about 8.26% to a price target of $127, down slightly from $133, reflecting confidence despite a recent price dip. The company expects a 4.42% increase in earnings per share to $1.89 and a 3.86% ris...

Analyst Insights
Bullish
1 hour ago
Xenon Pharmaceuticals stock plunges 27.6% after pausing clinical trials due to safety concerns.

Xenon Pharmaceuticals stock plunges 27.6% after pausing clinical trials due to safety concerns.

Xenon Pharmaceuticals halted new patient enrollment in its psychiatry clinical trials for the drug azetukalner after reports of neuropsychiatric side effects. This pause led to a sharp 27.6% drop in its stock price, marking its worst day since 2017. ...

Market News
Bearish
2 hours ago
Innate Pharma beats EPS estimates and secures $75M deal with Sobi, boosting cash runway to 2028

Innate Pharma beats EPS estimates and secures $75M deal with Sobi, boosting cash runway to 2028

Innate Pharma reported an EPS of -$0.24, beating analyst estimates of -$0.29, and revenue of $6.5 million, slightly above expectations. The company secured a strategic partnership with Sobi for its drug lacutamab, receiving a $75 million upfront paym...

Company Fundamentals
Bullish
2 hours ago
Paychex to report Q1 2027 earnings with expected EPS of $1.32 and $1.63B revenue on Sept 23

Paychex to report Q1 2027 earnings with expected EPS of $1.32 and $1.63B revenue on Sept 23

Paychex, a provider of human capital management solutions, will release its Q1 fiscal 2027 earnings on September 23, 2026. Analysts expect earnings per share (EPS) of $1.32, up from $1.22 last year, and revenue of about $1.63 billion, higher than las...

Company Fundamentals
Bullish
3 hours ago
Lennox declares quarterly dividend of $1.36 per share payable October 15, 2026

Lennox declares quarterly dividend of $1.36 per share payable October 15, 2026

Lennox's board approved a quarterly cash dividend of $1.36 per share, payable on October 15, 2026, to shareholders recorded by September 30, 2026. This dividend reflects Lennox's ongoing commitment to returning value to its investors. Lennox is a lea...

Company Fundamentals
Neutral
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App